Apoptose
Les inhibiteurs de l'apoptose sont des composés qui empêchent ou retardent le processus de mort cellulaire programmée, connu sous le nom d'apoptose. Ces inhibiteurs sont essentiels pour étudier les mécanismes de survie cellulaire et sont utilisés pour enquêter sur les maladies où l'apoptose est dysrégulée, telles que le cancer, les troubles neurodégénératifs et les maladies auto-immunes. En modulant l'apoptose, ces inhibiteurs peuvent aider au développement de thérapies visant à contrôler la mort cellulaire. Chez CymitQuimica, nous offrons une sélection complète d'inhibiteurs de l'apoptose de haute qualité pour soutenir vos recherches en biologie cellulaire, oncologie et domaines connexes.
Sous-catégories appartenant à la catégorie "Apoptose"
- ASK(6 produits)
- BCL(11 produits)
- Caspase(125 produits)
- FOXO1(3 produits)
- IAP(66 produits)
- Mdm2(12 produits)
- PD-1/PD-L1(125 produits)
- PDK(9 produits)
- PERK(25 produits)
- Sérine/thréonine kinase(15 produits)
- Survivant(13 produits)
- TNF(92 produits)
- c-RET(51 produits)
- p53(62 produits)
Affichez 6 plus de sous-catégories
5593 produits trouvés pour "Apoptose"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
ZLMT-12
<p>ZLMT-12: tacrine derivative, inhibits CDK2/CDK9, weak on AChE/BuChE, anti-proliferative, low toxicity, blocks S/G2/M phase, induces apoptosis.</p>Formule :C26H31ClN6OCouleur et forme :SolidMasse moléculaire :479.02BRD-K20733377
CAS :<p>BRD-K20733377 is a Bcl-2 inhibitor that exhibits selective cytotoxicity toward senescent cells, specifically inhibiting the activity of etoposide-induced senescent IMR-90 cells with an IC50 of 10.7 μM. Additionally, BRD-K20733377 reduces the mRNA expression of aging-related genes p16, p21, and KI67 in aged mouse models.</p>Formule :C23H18N4O3SCouleur et forme :SolidMasse moléculaire :430.48BRD-K44839765
CAS :<p>BRD-K44839765 selectively targets Bcl-2, exhibiting an IC50 of 5.6 μM in IMR-90 cells. This compound is also orally active.</p>Formule :C23H19N3O2S2Couleur et forme :SolidMasse moléculaire :433.55Soquelitinib
CAS :<p>Soquelitinib (CPI-818) is a selective ITK inhibitor， inhibits tumor growth,T-cell, up-regulatCXCR3, IFNγ, TNFα, and CD107a expression in normal CD8 cells.</p>Formule :C25H30N4O4S2Degré de pureté :99.54%Couleur et forme :SolidMasse moléculaire :514.66Topo I/COX-2-IN-1
<p>Topo I/COX-2-IN-1: potent dual inhibitor; IC50 0.24μM (COX-2), 4.42μM (Topo I); anti-cancer; induces apoptosis, halts migration.</p>Formule :C21H18ClFN2O3Couleur et forme :SolidMasse moléculaire :400.83Spliceostatin A
CAS :<p>Spliceostatin A is an anticancer agent and splicing inhibitor that induces apoptosis by inducing cell cycle arrest in the G1 and G2/M phases.</p>Formule :C28H43NO8Degré de pureté :94.66%Couleur et forme :SolidMasse moléculaire :521.643ASTX295
CAS :<p>ASTX295 is a selective mouse double minute 2 (MDM2) antagonist with an IC50 value of less than 1 nM. It specifically inhibits the interaction between MDM2 and p53, reactivating wild-type (WT) TP53, which subsequently induces the expression of related transcriptional targets, leading to cell death and cell cycle arrest. ASTX295 holds potential for research in lymphoid malignancies such as diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and T-cell lymphoma.</p>Formule :C33H34Cl2FNO6Couleur et forme :SolidMasse moléculaire :630.531p53 Activator 14
CAS :<p>p53 Activator 14 (Compound 7A) is a derivative of Neratinib that can induce DNA damage and activate p53, thereby inhibiting the proliferation of various cancer cells, with an IC50 of 7.21 μM for HCT116 cells. This compound hinders adhesion, migration, and invasion of HCT116 cells, disrupts the cell cycle, and triggers apoptosis. In addition, p53 Activator 14 exhibits anti-tumor properties and inhibits angiogenesis in the chick embryo chorioallantoic membrane (CAM) model.</p>Formule :C28H29ClN4O3Couleur et forme :SolidMasse moléculaire :505.008VEGFR-2-IN-11
<p>VEGFR-2-IN-11 is a potent inhibitor of VEGFR-2 (IC50: 60.27 nM) with an IC50 value of 60.27 nM, which induces apoptosis and has anticancer activity.</p>Formule :C29H22BrN5SCouleur et forme :SolidMasse moléculaire :552.49PAK4-IN-5
<p>PAK4-IN-5 (Compound 12i) is a potent inhibitor of PAK4 (IC50: PAK4 at 7.68 nM, PAK1 at 1872.01 nM) that forms stable interactions with the PAK4 enzyme. This compound effectively inhibits the proliferation and migration potential of MDA-MB-231 cells by hindering the phosphorylation of PAK4 and LIMK1. Additionally, PAK4-IN-5 arrests the cell cycle in the G0/G1 phase, induces apoptosis, and prompts the production of reactive oxygen species. The LD50 in mice is greater than 500 mg/kg (oral).</p>Formule :C31H28ClN5OCouleur et forme :SolidMasse moléculaire :522.04BMS-751324
CAS :<p>BMS-751324: p38α MAPK inhibitor with carbamyl-methyl, esters, phosphate from HPA. Reduces rat arthritis swelling and TNFα.</p>Formule :C32H35N6O10PCouleur et forme :SolidMasse moléculaire :694.63HDAC-IN-81
CAS :<p>HDAC-IN-81 (Compound 11g) is an HDAC inhibitor capable of effectively inhibiting HDAC1 with an IC50 value of 4.5 nM. Additionally, it exhibits anticancer activity by inhibiting cell proliferation and can induce cell apoptosis (apoptosis).</p>Formule :C20H27N3O3Couleur et forme :SolidMasse moléculaire :357.45RSK-IN-2
CAS :<p>RSK-IN-2 (Compound 3e) is an inhibitor of RSK, showing IC50 values of 37.89 nM for RSK2, 30.78 nM for RSK1, 20.51 nM for RSK3, and 91.28 nM for RSK4. It suppresses tumor cell proliferation, induces apoptosis, and causes cell cycle arrest at the G2/M phase.</p>Formule :C25H30ClN7O3Couleur et forme :SolidMasse moléculaire :512.004MB710
CAS :<p>MB710 is an amino-benzothiazole derivative that tightly binds to the Y220C pocket and stabilizes p53-Y220C in vitro.</p>Formule :C16H16IN3O3SDegré de pureté :99.02%Couleur et forme :SolidMasse moléculaire :457.29Verrucarin A
CAS :<p>Verrucarin A, a mycotoxin from Myrothecium verrucaria, inhibits protein synthesis, leukemia growth, and triggers apoptosis.</p>Formule :C27H34O9Couleur et forme :SolidMasse moléculaire :502.55TRPM7-IN-1
CAS :<p>TRPM7-IN-1 (compound SUD) is a benzamide-urea derivative and an effective inhibitor of TRPM7. This compound induces cell cycle arrest and apoptosis in MCF-7 and BGC-823 cells, reducing their migration capabilities. It decreases vimentin expression while increasing E-cadherin expression. TRPM7-IN-1 reduces TRPM7-like currents and inhibits TRPM7 expression by activating the PI3K/Akt signaling pathway. This compound shows potential as a therapeutic agent for reducing breast and gastric cancer metastasis by targeting TRPM7 expression and activity.</p>Formule :C23H25N5O3Couleur et forme :SolidMasse moléculaire :419.48MLS-0053105
CAS :<p>MLS-0053105, a chloromaleimide, functions as a selective inhibitor of BFL-1, exhibiting an IC50 of 0.4 µM against Bfl-1/F-Bid. Its inhibitory potency is over tenfold lower for Bcl-W, Bcl-2, and Bcl-XL, and it shows no activity against Bcl-B and Mcl-1.</p>Formule :C15H14Cl3N3O2Couleur et forme :SolidMasse moléculaire :374.65AKT-IN-3
CAS :<p>AKT-IN-3: potent oral Akt inhibitor with low hERG blockage. IC50: 1.4-1.7 nM for Akt1-3. Inhibits AGC kinases like PKA, PKC.</p>Formule :C23H23Cl2F2N5O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :526.36RET-IN-10
CAS :<p>RET-IN-10: Potent RET inhibitor, may treat congenital megacolon and tumors (Patent WO2021135938A1, compound 18).</p>Formule :C29H28N8OSCouleur et forme :SolidMasse moléculaire :536.65PD-1/PD-L1-IN-30
CAS :<p>PD-1/PD-L1-IN-30: Cancer research inhibitor with 0.018 μM IC50.</p>Formule :C29H28F3NO5Couleur et forme :SolidMasse moléculaire :527.53
